Tokyo: Life Sciences and Health Care Horizons 2019

Key Life Sciences issues for Japanese companies: focus on (1) digital health, (2) cell, tissue, and gene therapies, and (3) cross-border transactions.

Essential corporate, tax, regulatory and IP issues for Japanese companies expanding in Europe

In the light of the continued increase in significant mergers and acquisitions (M&A) and licensing transactions worldwide, in particular the significant increase of out-bound...

[Seminar]Strategic considerations for effective, profitable and successful M&A and licensing in Europe

During the past 2 years, the number of significant M&A and licensing transactions as increased worldwide and this trend appears set to continue for the foreseeable future. In the pharma ...

Loading data